Cardiff Oncology News and Activities
Presence
Headquarters: United States (USA)
Cardiff Oncology is a company listed under the stock ticker CRDF (US).
Executives
View the org chart displaying its 18 main executives
Most searched biographies at Cardiff Oncology
- Mani Mohindru, President and Chief Executive Officer
- James Armitage, Director
- Renee Tannenbaum, Independent Director
Popular executive movements at Cardiff Oncology
- Josh Muntner has joined the company as Chief Financial Officer (posted on April 12 2026).
- Mani Mohindru, who was Interim Chief Executive Officer, is promoted to President and Chief Executive Officer (posted on April 12 2026).
- Ajay Aggarwal will join the company as Chief Operating Officer on Apr. 27, 2026 (posted on April 12 2026).
Click here to view some more movements at Cardiff Oncology
Create your alert
to follow the executive moves at Cardiff Oncology.
Biotechnology
Cardiff Oncology has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Cardiff Oncology
- Press Releases - Cardiff Oncology, Inc.
- Press Releases - Cardiff Oncology, Inc.
- Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference - Cardiff Oncology, Inc.
- Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting - Cardiff Oncology, Inc.
- Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC - Cardiff Oncology, Inc.
- Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update - Cardiff Oncology, Inc.
- Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Cardiff Oncology, Inc.
- Press Releases - Cardiff Oncology, Inc.
- Press Releases - Cardiff Oncology, Inc.
- Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity - Cardiff Oncology, Inc.
- View more press releases Close
Social media about Cardiff Oncology
- Cardiff Oncology on Wikipedia, Google News & Yahoo Finance
- Cardiff Oncology on LinkedIn, X (Twitter) & YouTube
